Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LGVN Longeveron Inc

Market Closed 06-26 16:00:00 EDT

0.7155

-0.0135

-1.85%

盘后0.7100

-0.0055-0.77%

19:24 EDT

High0.7500	Low0.6997	Vol304.02K
Open0.7285	D1 Closing0.7290	Amplitude6.90%
Mkt Cap22.61M	Tradable Cap19.50M	Total Shares31.60M
T/O217.95K	T/O Rate1.12%	Tradable Shares27.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LGVN","market":"US","secType":"STK","nameCN":"Longeveron Inc","latestPrice":0.7155,"timestamp":1782504000000,"preClose":0.729,"halted":0,"volume":304021,"hourTrading":{"tag":"盘后","latestPrice":0.71,"preClose":0.7155,"latestTime":"19:24 EDT","volume":5428,"amount":3820.1271,"timestamp":1782516256306,"change":-0.0055,"changeRate":-0.007687,"amplitude":0.021663},"delay":0,"changeRate":-0.01851851851851846,"floatShares":27255300,"shares":31597952,"eps":-1.119466,"marketStatus":"Market Closed","change":-0.0135,"latestTime":"06-26 16:00:00 EDT","open":0.7285,"high":0.75,"low":0.6997,"amount":217951.43881599998,"amplitude":0.068999,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.119466,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782720000000},"marketStatusCode":7,"adr":0,"listingDate":1613106000000,"exchange":"NASDAQ","adjPreClose":0.729,"preHourTrading":{"tag":"盘前","latestPrice":0.7748,"preClose":0.729,"latestTime":"07:53 EDT","volume":3344,"amount":2594.90798512,"timestamp":1782474807112,"change":0.0458,"changeRate":0.062826,"amplitude":0.111111},"postHourTrading":{"tag":"盘后","latestPrice":0.71,"preClose":0.7155,"latestTime":"19:24 EDT","volume":5428,"amount":3820.1271,"timestamp":1782516256306,"change":-0.0055,"changeRate":-0.007687,"amplitude":0.021663},"volumeRatio":1.2535397680176597},"requestUrl":"/m/hq/s/LGVN/tweets","defaultTab":"tweets","newsList":[{"id":"2644086763","title":"Longeveron says new Phase 2a analysis of laromestrocel in mild Alzheimer’s accepted for AAIC 2026 poster presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2644086763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644086763?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:20","pubTimestamp":1781788821,"startTime":"0","endTime":"0","summary":"Longeveron flagged an additional analysis from its Phase 2a CLEAR MIND study of laromestrocel in mild Alzheimer’s disease.Results were already published in Nature Medicine in March 2025, supporting potential benefit and backing continued clinical development.The new analysis will be presented at the 2026 Alzheimer’s Association International Conference in London on July 13.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL7RjP7p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","IE00BN0W2V16.EUR","BK4112","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014039.USD","LU2210149790.SGD","LGVN","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014021.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4139","BK4585","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642427498","title":"Longeveron wins EMA small, medium-sized enterprise status","url":"https://stock-news.laohu8.com/highlight/detail?id=2642427498","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642427498?lang=en_us&edition=fundamental","pubTime":"2026-06-09 21:26","pubTimestamp":1781011562,"startTime":"0","endTime":"0","summary":"Longeveron received small or medium-sized enterprise status from the European Medicines Agency, a designation that can lower fees.Status also supports earlier regulatory engagement during development of its lead cell therapy candidate laromestrocel .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief on June 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL5zzsHF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642498113","title":"Longeveron Granted Small or Medium-Sized Enterprise (SME) Status by the European Medicines Agency (Ema)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642498113","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642498113?lang=en_us&edition=fundamental","pubTime":"2026-06-09 21:20","pubTimestamp":1781011200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUABRCPXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642498269","title":"Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642498269","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642498269?lang=en_us&edition=fundamental","pubTime":"2026-06-09 21:20","pubTimestamp":1781011200,"startTime":"0","endTime":"0","summary":"MIAMI, June  09, 2026  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-rel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/09/3308957/0/en/Longeveron-Granted-Small-or-Medium-sized-Enterprise-SME-Status-by-the-European-Medicines-Agency-EMA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN","EMA","BK4150","BK4081","EPV","BK4575","MDCO","MSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641412832","title":"Longeveron Announces CFO Transition to Internal Successor","url":"https://stock-news.laohu8.com/highlight/detail?id=2641412832","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641412832?lang=en_us&edition=fundamental","pubTime":"2026-06-06 05:19","pubTimestamp":1780694382,"startTime":"0","endTime":"0","summary":"Longeveron ( ($LGVN) ) has shared an announcement. On June 1, 2026, Longeveron Inc. announced that Chief Financial Officer Lisa Locklear will step ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/longeveron-announces-cfo-transition-to-internal-successor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/longeveron-announces-cfo-transition-to-internal-successor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641140304","title":"BRIEF-Longeveron -   On June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641140304","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641140304?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:35","pubTimestamp":1780691728,"startTime":"0","endTime":"0","summary":"BRIEF-Longeveron -   On June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026 - SEC FilingJune 5  - Longeveron Inc LGVN.O:LONGEVERON -   ON JUNE 1, LISA LOCKLEAR TO STEP DOWN AS CFO EFFECTIVE JULY 10, 2026 - SEC FILINGLONGEVERON - ANTICIPATES MARIE WASHBURN TO BE ELEVATED TO CFO PENDING FINAL CONTRACT - SEC FILINGSource text: [ID:n0001213900-26-065788]Further company coverage: LGVN.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nFWN42D05C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641147045","title":"Longeveron -   on June 1, Lisa Locklear to Step Down as CFO Effective July 10, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641147045","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641147045?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:24","pubTimestamp":1780691047,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nFWN42D05C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641046147","title":"Longeveron - Anticipates Marie Washburn to Be Elevated to CFO Pending Final Contract - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641046147","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641046147?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:24","pubTimestamp":1780691047,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nFWN42D05C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640892168","title":"Longeveron to present at BIO International Convention 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640892168","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640892168?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:15","pubTimestamp":1780578920,"startTime":"0","endTime":"0","summary":"Longeveron will attend the BIO International Convention on June 22-25, 2026 in San Diego.A corporate presentation is scheduled for June 24, 2026 at 2:15 p.m. PT.Management plans partnering meetings tied to laromestrocel programs in HLHS, Alzheimer’s disease, pediatric dilated cardiomyopathy, aging-related frailty.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL5Kyvvl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","IE00BN0W2V16.EUR","BK4112","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014039.USD","LU2210149790.SGD","LGVN","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014021.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4139","BK4585","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637878512","title":"Longeveron shifts to capital-light model, targets licensing partners for laromestrocel","url":"https://stock-news.laohu8.com/highlight/detail?id=2637878512","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637878512?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:06","pubTimestamp":1779307612,"startTime":"0","endTime":"0","summary":"Longeveron shifted to a more capital-efficient plan centered on licensing partnerships for its stem cell therapy laromestrocel, aiming to rely on partners’ commercial scale and funding to advance development.Strategy prioritizes the Phase 2b ELPIS II readout in hypoplastic left heart syndrome, with top-line 12-month data expected in August 2026, to support FDA discussions on a potential path to a biologics license application.Planning includes advancing pediatric dilated cardiomyopathy into a single Phase 2 registrational trial in 2027, contingent on financing or a partnership.Alzheimer’s disease development is positioned for partnering and non-dilutive funding, based on an FDA-aligned single Phase 2/3 adaptive trial design that could support a future biologics license application.Capital plan targets lower cash burn and reduced dilution, supported by a March private placement for up to USD 30 million, with USD 15 million upfront and up to USD 15 million tied to ELPIS II results and sh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL4wmq0b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B3QW5Z07.USD","NDAQ","SG9999014013.SGD","SG9999014021.USD","LU2095319765.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","LU2210149790.SGD","LU0314104364.USD","IE00BKPKM429.USD","BK4112","SG9999014005.SGD","BK4588","BK4585","LGVN","IE00BN0W2V16.EUR","SG9999014039.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637878518","title":"Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2637878518","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637878518?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:05","pubTimestamp":1779307500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUA2MLJVC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635557537","title":"Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635557537","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635557537?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:42","pubTimestamp":1778704943,"startTime":"0","endTime":"0","summary":"Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 44.12 percent increase over losses of $(0.34) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52545344/longeveron-q1-eps-0-19-misses-0-16-estimate-sales-398-000k-beat-314-667k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753739","title":"Longeveron Q1 revenue rises, beats analyst estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753739","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753739?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:24","pubTimestamp":1778703879,"startTime":"0","endTime":"0","summary":"Longeveron Q1 revenue rises, beats analyst estimatesOverviewUS biotech firm's Q1 revenue rose and beat analyst expectationsNet loss for Q1 narrowed from prior yearCompany closed $30 mln private placem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL1N41Q166:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758296","title":"BRIEF-Longeveron Q1 EPS USD -0.19","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758296","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758296?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702746,"startTime":"0","endTime":"0","summary":"BRIEF-Longeveron Q1 EPS USD -0.19\n\n\nMay 13 (Reuters) - Longeveron Q1 revenue USD 378 thousand.\n\nQ1 gross profit USD 264 thousand\nQ1 operating expenses USD 5.039 million\nQ1 income from operations USD -4.775 million\nQ1 net income USD -4.736 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLXEDCA43:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635581997","title":"Longeveron Q1 Revenue USD 378 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2635581997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635581997?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702701,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLXEDCA43:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758067","title":"Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758067","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758067?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702700,"startTime":"0","endTime":"0","summary":"Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3294435/0/en/Longeveron-Announces-2026-First-Quarter-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AD","BK4139","BK4150","IND","LGVN","MSC","BK4575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635675828","title":"Longeveron Q1 net loss narrows 6% to $4.74 million; revenue rises to $398,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2635675828","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635675828?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:04","pubTimestamp":1778702681,"startTime":"0","endTime":"0","summary":"Longeveron posted a net loss of $4.74 million for the quarter ended March 31, 2026, narrowing 6% from a year earlier.Revenue in the quarter rose 4.46% to $398,000, while cost of revenues increased to $134,000.Operating loss improved to $4.78 million, as total operating expenses fell 7.64% to $5.04 million.Cash and cash equivalents totaled $15.8 million at March 31, 2026, with the company expecting that balance to fund operations into the fourth quarter of 2026.ELPIS II Phase 2b trial in hypoplastic left heart syndrome remains fully enrolled, with top-line results anticipated in August 2026 following an FDA Type C meeting that said right-ventricle ejection fraction is not an appropriate efficacy endpoint.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL4dYj9g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634237211","title":"Longeveron reports DMC approval for laromestrocel study to continue as designed","url":"https://stock-news.laohu8.com/highlight/detail?id=2634237211","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634237211?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:09","pubTimestamp":1778530181,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced that the independent data monitoring committee, or DMC, has completed its final prespecified data review for the ongoin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-reports-dmc-approval-for-laromestrocel-study-to-continue-as-designed-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-reports-dmc-approval-for-laromestrocel-study-to-continue-as-designed-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634340442","title":"Longeveron Cut to Hold From Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2634340442","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634340442?lang=en_us&edition=fundamental","pubTime":"2026-05-12 03:51","pubTimestamp":1778529060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LGVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 15:51 ET (19:51 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634823530","title":"Longeveron downgraded to Hold from Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2634823530","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634823530?lang=en_us&edition=fundamental","pubTime":"2026-05-11 23:43","pubTimestamp":1778514209,"startTime":"0","endTime":"0","summary":"Maxim downgraded Longeveron (LGVN) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-downgraded-to-hold-from-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-downgraded-to-hold-from-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longeveron.com","stockEarnings":[{"period":"1week","weight":-0.1275},{"period":"1month","weight":-0.0999},{"period":"3month","weight":-0.2223},{"period":"6month","weight":0.3437},{"period":"1year","weight":-0.4496},{"period":"ytd","weight":0.414}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.146765},{"month":2,"riseRate":0,"avgChangeRate":-0.052773},{"month":3,"riseRate":0.5,"avgChangeRate":0.193379},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.138428},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.132971},{"month":6,"riseRate":0.666667,"avgChangeRate":0.089689},{"month":7,"riseRate":0.6,"avgChangeRate":0.185232},{"month":8,"riseRate":0,"avgChangeRate":-0.329414},{"month":9,"riseRate":0.2,"avgChangeRate":-0.104571},{"month":10,"riseRate":0.4,"avgChangeRate":-0.0027},{"month":11,"riseRate":0.4,"avgChangeRate":1.29104},{"month":12,"riseRate":0,"avgChangeRate":-0.282059}],"exchange":"NASDAQ","name":"Longeveron Inc","nameEN":"Longeveron Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Longeveron Inc,LGVN,Longeveron Inc股票,Longeveron Inc股票老虎,Longeveron Inc股票老虎国际,Longeveron Inc行情,Longeveron Inc股票行情,Longeveron Inc股价,Longeveron Inc股市,Longeveron Inc股票价格,Longeveron Inc股票交易,Longeveron Inc股票购买,Longeveron Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction